Mavorixafor (AMD-070)

Description: AMD-070 (also known as AMD11070, AMD070, X4P-001 and mavorixafor) is a potent, selective and orally bioavailable antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay, it inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs. The CXC chemokine receptor CXCR2 is upregulated in a variety of different tumor cell types and involved in tumor cell proliferation and progression. Inhibition of CXCR2 led to reduced metastasis and decreased tumorigenesis. As a CXCR2 antagonist, SX-682 has the potential to treat cancer. AMD-070 has been evaluated in phase I/II studies in different solid tumors by X4 Pharmaceuticals. This compound also has the potential use for the treatment of HIV-1 infection.

References: PLoS One. 2016 Mar 21; 11(3):e0151765; J Med Chem. 2010 Apr 22; 53(8):3376-88.

Related CAS#:880549-30-4 (HCl)